Liberty Capital Corporation - Series C GCI Group (GLIBK)
Live price chart, market sentiment, and community perspectives for Liberty Capital Corporation - Series C GCI Group (NASDAQ: GLIBK).
Live price chart, market sentiment, and community perspectives for Liberty Capital Corporation - Series C GCI Group (NASDAQ: GLIBK).
On our desk, the recent Q2 2026 earnings report for Liberty Capital (GLIBK) was a clear disappointment. Posting an EPS of $0.40 against consensus estimates ranging up to $1.15 or $1.18 heavily penalizes the stock's short-term multiple expansion thesis. Even though GAAP revenue held flat at $261 million due to data growth offsetting the 2025 video business exit, the operational margin contraction reflected in an 11% decline in Adjusted OIBDA ($96 million) is hard to ignore.
In our research protocol, evaluating the fundamental operational adjustments requires parsing the revenue mix shifts. Consumer revenue slipped 2% YoY to $117 million due to the complete exit of the video business, though this was partially cushioned by wireless gains. Meanwhile, business revenue saw growth driven entirely by data operations, balancing out the top line to $261 million overall.
Watching the technical charts and recent options flow on GLIBA and GLIBK, I notice above-average volume over the last 30 days and a 22% price recovery over the same timeframe. However, with two active Wall Street sell ratings and a consensus target sitting at zero according to certain aggregators, market participants are heavily divided between near-term momentum and fundamental earnings friction.
From a portfolio management perspective, Southeastern Asset Management’s Small-Cap Fund highlights that portfolio holdings remain attractive based on P/V and P/FCF metrics, though market winners have stretched far beyond fair value. Rebranding for expansion under Liberty Capital Corporation keeps GLIBK positioned squarely within strategies looking for unweighted multiples and long-term free cash flow per share expansion.
Analyzing the upcoming Q3 consensus estimates, analysts are projecting a bounce back with expected revenue of $273.98 million and an EPS estimate of $0.99. Given that GLIBK missed previous estimates quite significantly, our internal models suggest maintaining a cautious stance until operational expenses and acquisition-related cost pressures begin to stabilize.
Explore plasma cleansing, somatic organ swaps, and BCI.